Drug Database
SI

sinteplase (Plasminer / tPA, Toyobo / sinteplase)

✓ Approved

Sanofi S.A · PLAT · Recombinant Proteins

What is sinteplase?

sinteplase is a recombinant proteins developed by Sanofi S.A. It is approved for therapeutic indications.

Drug Profile

Brand NamesPlasminer, tPA, Toyobo, sinteplase
CompanySanofi S.A
Drug ClassRecombinant Proteins
Molecular TargetPLAT
StatusApproved
Sources: ClinicalTrials.gov, Sanofi S.A

Mechanism of Action

Molecular Targets

sinteplase acts on 1 molecular target:

PLATplasminogen activator, tissue type (TPA, T-PA)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

sinteplase is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Cardiac disordersCardiovascular disorder✓ Approved
Vascular disordersThrombosis✓ Approved

Ask about sinteplase